"Devising medical countermeasures against biological threats, whether they arise naturally or are the result of deliberate human action, is a top priority for NIAID," says NIAID Director Anthony S. Fauci, M.D. "These new awards support research needed to better understand and defend against disease-causing microbes and provide funds to construct facilities where such research can be performed safely."
Regional Biocontainment Laboratories
The four new labs will join nine other NIAID-funded BSL-3 labs in the Institute's Regional Biocontainment Laboratory (RBL) program. In 2002, a panel of experts convened to provide guidance to NIAID on its biodefense agenda cited insufficient BSL-3 and BSL-4 space as a major barrier to research progress. As part of its response, NIAID established the RBL program to fund the design, construction and commissioning of state-of-the-art BSL-3 labs at sites spanning the country. The institutions receiving the new awards and the principal investigators are as follows:
More information about NIAID's biocontainment facility construction program and a map of the previously awarded sites is at <
Contact: Anne A. Oplinger
NIH/National Institute of Allergy and Infectious Diseases